Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Luye Pharma Group Ltd (2186)
Luye Pharma Group Ltd stock price live, this page displays HK 2186 stock exchange data. View the 2186 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Luye Pharma Group Ltd real time stock price chart below.
What Is the Luye Pharma Group Ltd Stock Price Today?
The Luye Pharma Group Ltd stock price today is 2.26.
What Is the Stock Symbol for Luye Pharma Group Ltd?
The stock symbol for Luye Pharma Group Ltd is "2186."
What Stock Exchange Does Luye Pharma Group Ltd Trade On?
Luye Pharma Group Ltd is listed and trades on the Hong Kong stock exchange.
Is Luye Pharma Group Ltd a Good Stock to Buy?
Determining whether Luye Pharma Group Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2186 quote. (ISIN: BMG570071099)
What Is the Luye Pharma Group Ltd Stock Price Today?
The Luye Pharma Group Ltd stock price today is 2.26.
What Is the Stock Symbol for Luye Pharma Group Ltd?
The stock symbol for Luye Pharma Group Ltd is "2186."
What Stock Exchange Does Luye Pharma Group Ltd Trade On?
Luye Pharma Group Ltd is listed and trades on the Hong Kong stock exchange.
Is Luye Pharma Group Ltd a Good Stock to Buy?
Determining whether Luye Pharma Group Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2186 quote. (ISIN: BMG570071099)
Hong Kong
Currency in HKD
2.26
-0.02(-0.88%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.22
2.28
52 wk Range
2.03
4.49
2186 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.222.28
52 wk Range
2.034.49
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2186 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
3.51
Upside
+55.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Luye Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.51
(+55.11% Upside)
Earnings
Latest Release
Mar 30, 2026
EPS / Forecast
0.08 / --
Revenue / Forecast
3.13B / --
Compare 2186 to Peers and Sector
Metrics to compare | 2186 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2186PeersSector | |
|---|---|---|---|---|
P/E Ratio | 12.8x | 17.2x | −0.5x | |
PEG Ratio | 0.48 | 0.16 | 0.00 | |
Price/Book | 0.5x | 2.8x | 2.6x | |
Price / LTM Sales | 1.3x | 2.9x | 3.1x | |
Upside (Analyst Target) | 53.7% | 39.6% | 55.1% | |
Fair Value Upside | Unlock | 16.4% | 7.2% | Unlock |
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by trauma or surgery, and for treatment of venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes mellitus; Seroquel, Seroquel XR, Erzofri; and Rivastigmine Multi-Day Transdermal, Rotigotine transdermal, Fentanyl, and Buprenorphine patches. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Boyoubei, a denosumab injection for the treatment of postmenopausal women with osteoporosis; and Boyouping, a dulaglutide injection for glycemic control in adults. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; develops, manufactures, and commercialises of biologics; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People’s Republic of China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Luye Pharma Group (2186) Stock Price Today?
The Luye Pharma Group stock price today is 2.26 HKD.
What Stock Exchange Does Luye Pharma Group Trade On?
Luye Pharma Group is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Luye Pharma Group?
The stock symbol for Luye Pharma Group is "2186."
What Is the Luye Pharma Group Market Cap?
As of today, Luye Pharma Group market cap is 9.03B HKD.
What Is Luye Pharma Group's Earnings Per Share (TTM)?
The Luye Pharma Group EPS (TTM) is 0.16.
From a Technical Analysis Perspective, Is 2186 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Luye Pharma Group Stock Split?
Luye Pharma Group has split 0 times.
How Many Employees Does Luye Pharma Group Have?
Luye Pharma Group has 5115 employees.
What is the current trading status of Luye Pharma Group (2186)?
As of May 20, 2026, Luye Pharma Group (2186) is trading at a price of 2.26 HKD, with a previous close of 2.28 HKD. The stock has fluctuated within a day range of 2.22 HKD to 2.28 HKD, while its 52-week range spans from 2.03 HKD to 4.49 HKD.
What Is Luye Pharma Group (2186) Price Target According to Analysts?
The average 12-month price target for Luye Pharma Group is 3.51 HKD, with a high estimate of 4.31167338 HKD and a low estimate of 2.69925244 HKD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +55.11% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.